273 related articles for article (PubMed ID: 19352380)
41. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
Corley DA; Kubo A; Zhao W; Quesenberry C
Gastroenterology; 2010 Jul; 139(1):93-101. PubMed ID: 20353792
[TBL] [Abstract][Full Text] [Related]
42. The Uncertainty of the Association Between Proton Pump Inhibitor Use and the Risk of Dementia: Prescription Sequence Symmetry Analysis Using a Korean Healthcare Database Between 2002 and 2013.
Park SK; Baek YH; Pratt N; Kalisch Ellett L; Shin JY
Drug Saf; 2018 Jun; 41(6):615-624. PubMed ID: 29397553
[TBL] [Abstract][Full Text] [Related]
43. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study.
Robertson DJ; Larsson H; Friis S; Pedersen L; Baron JA; Sørensen HT
Gastroenterology; 2007 Sep; 133(3):755-60. PubMed ID: 17678921
[TBL] [Abstract][Full Text] [Related]
44. Proton-pump inhibitor use and the development of new ischemic heart disease in non-cardiac chest pain patients.
Kim Y; Ganocy S; Fass R
Neurogastroenterol Motil; 2020 Jul; 32(7):e13844. PubMed ID: 32281192
[TBL] [Abstract][Full Text] [Related]
45. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
46. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
47. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
48. Does long-term medication with a proton pump inhibitor induce a tolerance to H2 receptor antagonist?
Hashimoto H; Kushikata T; Kudo M; Hirota K
J Gastroenterol; 2007 Apr; 42(4):275-8. PubMed ID: 17464455
[TBL] [Abstract][Full Text] [Related]
49. Effects of daily treatment with acid suppressants for stress ulcer prophylaxis on risk of ventilator-associated events.
Li X; Klompas M; Menchaca JT; Young JG
Infect Control Hosp Epidemiol; 2020 Feb; 41(2):187-193. PubMed ID: 31818336
[TBL] [Abstract][Full Text] [Related]
50. Use of proton pump inhibitors and risk of pancreatic cancer.
Hicks B; Friis S; Pottegård A
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
[TBL] [Abstract][Full Text] [Related]
51. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis.
Huang KW; Kuan YC; Luo JC; Lin CL; Liang JA; Kao CH
Eur J Intern Med; 2016 Jul; 32():91-5. PubMed ID: 27139916
[TBL] [Abstract][Full Text] [Related]
52. Histamine H2-Blocker and Proton Pump Inhibitor Use and the Risk of Pneumonia in Acute Stroke: A Retrospective Analysis on Susceptible Patients.
Arai N; Nakamizo T; Ihara H; Koide T; Nakamura A; Tabuse M; Miyazaki H
PLoS One; 2017; 12(1):e0169300. PubMed ID: 28085910
[TBL] [Abstract][Full Text] [Related]
53. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.
Brusselaers N; Lagergren J; Engstrand L
Cancer Epidemiol; 2019 Oct; 62():101585. PubMed ID: 31445426
[TBL] [Abstract][Full Text] [Related]
54. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs.
Sturkenboom MC; Burke TA; Tangelder MJ; Dieleman JP; Walton S; Goldstein JL
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1137-47. PubMed ID: 14653834
[TBL] [Abstract][Full Text] [Related]
55. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.
Waldum HL; Sørdal Ø; Fossmark R
Scand J Gastroenterol; 2018 Jun; 53(6):639-642. PubMed ID: 29852782
[TBL] [Abstract][Full Text] [Related]
56. Risk of systemic autoimmune diseases in gastric disease patients with proton pump inhibitor use: a nationwide cohort study in Taiwan.
Chen HY; Lin JJ; Yang B; Lin MC
Clin Rheumatol; 2020 Sep; 39(9):2773-2780. PubMed ID: 32152918
[TBL] [Abstract][Full Text] [Related]
57. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
58. Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center.
McCaleb RV; Gandhi AS; Clark SM; Clemmons AB
Ann Pharmacother; 2016 Jul; 50(7):541-7. PubMed ID: 27091869
[TBL] [Abstract][Full Text] [Related]
59. Lack of Association Between Proton Pump Inhibitor Use and Cognitive Decline.
Wod M; Hallas J; Andersen K; García Rodríguez LA; Christensen K; Gaist D
Clin Gastroenterol Hepatol; 2018 May; 16(5):681-689. PubMed ID: 29391266
[TBL] [Abstract][Full Text] [Related]
60. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies.
Ahn JS; Eom CS; Jeon CY; Park SM
World J Gastroenterol; 2013 Apr; 19(16):2560-8. PubMed ID: 23674860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
